Loxo Oncology, a biotech developing small molecule therapeutics to treat solid tumors, announced terms for its IPO on Monday. The Stamford, CT-based company plans to raise $57 million by offering 4.4 million shares at a price range of $12 to $14. At the midpoint...read more
Last week’s 11 pricings brought the year’s total to 221, the highest count since 2000, and large deals from Hilton Worldwide (HLT) and ARAMARK (ARMK) lifted the year’s total proceeds above $50 billion, also a first since 2000. With 69 IPOs...read more
TetraLogic Pharmaceuticals, which is developing small molecule therapeutics for the treatment of cancer, raised $50 million by offering 7.2 million shares at $7. TetraLogic Pharmaceuticals plans to list on the NASDAQ under the symbol TLOG. TetraLogic...read more
TetraLogic Pharmaceuticals, which is developing small molecule therapeutics for the treatment of cancer, lowered the proposed deal size for its upcoming IPO on Tuesday. The Malvern, PA-based company now plans to raise $46 million by offering 6.5 million shares...read more
Cancer biotech Loxo Oncology sets terms for $57 million IPO
Loxo Oncology, a biotech developing small molecule therapeutics to treat solid tumors, announced terms for its IPO on Monday. The Stamford, CT-based company plans to raise $57 million by offering 4.4 million shares at a price range of $12 to $14. At the midpoint...read more
US IPO Recap: 221 IPOs for the year, most in a decade
Last week’s 11 pricings brought the year’s total to 221, the highest count since 2000, and large deals from Hilton Worldwide (HLT) and ARAMARK (ARMK) lifted the year’s total proceeds above $50 billion, also a first since 2000. With 69 IPOs...read more
TetraLogic prices relaunched IPO at $7
TetraLogic Pharmaceuticals, which is developing small molecule therapeutics for the treatment of cancer, raised $50 million by offering 7.2 million shares at $7. TetraLogic Pharmaceuticals plans to list on the NASDAQ under the symbol TLOG. TetraLogic...read more
TetraLogic cuts proposed IPO price to $7, deal size is now $46 million
TetraLogic Pharmaceuticals, which is developing small molecule therapeutics for the treatment of cancer, lowered the proposed deal size for its upcoming IPO on Tuesday. The Malvern, PA-based company now plans to raise $46 million by offering 6.5 million shares...read more